Dawn Langdon shares her insights on significant recent developments including the Brief International Cognitive Assessment for MS (BICAMS), a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in MS, as well as an important new study on Benefit and Risk information for Medication in MS (BRIMMS).
1. What are the most significant recent developments in your area? (0:05)
2. Can you tell us about the presentations you have been involved in here? (0:38)
3. What challenges do you face when treating patients with MS? (2:41)
Speaker disclosures: Dawn Langdon is a speaker bureau participant for Bayer, Merck, Almirall, Excemed, TEVA, Roche, Novartis, Biogen and Sanofi; consultant to Novartis, Bayer, Merck, Biogen, Teva and Sanofi; receives research grants from Bayer, Merck, Novartis and Biogen. All are paid to Royal Holloway, University of London.
Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.
